Clinical Trial

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-10-08; most recent amendment 2025-09-12.
Status change: Not Yet Recruiting → Recruiting 2024-01-11
Trial Details
NCT Number NCT06082102
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Relapsed/Refractory Marginal Zone Lymphoma
Enrollment 324 participants
Start Date 2023-12-19
Primary Completion 2028-08-31 (estimated)
Study Completion 2030-02-25 (estimated)
Updated on ClinicalTrials.gov 2025-09-15